Moderator Of 6 Sessions
An overview of the factors influencing the effectiveness of CGM systems. Discuss expectations and documented evidence for the use of the Eversense CGM System.
Exchange of clinical experiences related to the use of the long-term, implantable CGM. Insight into the research and development of Eversense.
It is estimated that more than 160 million patients worldwide live with chronic kidney disease and type 2 diabetes. They are at high risk for cardiovascular events and progressive renal failure. Unmet educational needs of HCPs include optimizing management of chronic kidney disease and Type 2 diabetes will be summarized. With the development of nonsteroidal mineralocorticoid receptor antagonists (MRA), the safety profile of MRA has also improved significantly, making mineralocorticoid receptor antagonism a potential, highly effective treatment option for slowing the progression of CKD in T2D. Finerenone is such novel nonsteroidal selective MRA with a high MR selectivity compared to spironolactone. It has favourable effects on cardiorenal outcomes in patients with stage 3 or 4 chronic kidney disease with increased albuminuria and type 2 diabetes. Two large trials ((FIDELIO-DKD, FIGARO-DKD) evaluated the effects of Finerenone on cardiorenal outcomes and demonstrated significant favourable effects. Results of these studies will be discussed. New treatment approaches for chronic kidney disease in diabetes will be highlighted.